Kelly CP - Search Results

1

Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A.

Taylor CP, Tummala S, Molrine D, Davidson L, Farrell RJ, Lembo A, Hibberd PL, Lowy I, Kelly CP. Taylor CP, et al. Among authors: kelly cp. Vaccine. 2008 Jun 25;26(27-28):3404-9. doi: 10.1016/j.vaccine.2008.04.042. Epub 2008 May 7. Vaccine. 2008. PMID: 18502001 Free PMC article. Clinical Trial.

2

Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding.

Kelly CP, Pothoulakis C, Orellana J, LaMont JT. Kelly CP, et al. Gastroenterology. 1992 Jan;102(1):35-40. doi: 10.1016/0016-5085(92)91781-x. Gastroenterology. 1992. PMID: 1309359 Free article.

3

Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit.

Kelly CP, Becker S, Linevsky JK, Joshi MA, O'Keane JC, Dickey BF, LaMont JT, Pothoulakis C. Kelly CP, et al. J Clin Invest. 1994 Mar;93(3):1257-65. doi: 10.1172/JCI117080. J Clin Invest. 1994. PMID: 7907603 Free PMC article.

4

Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins.

Kelly CP, Pothoulakis C, Vavva F, Castagliuolo I, Bostwick EF, O'Keane JC, Keates S, LaMont JT. Kelly CP, et al. Antimicrob Agents Chemother. 1996 Feb;40(2):373-9. doi: 10.1128/AAC.40.2.373. Antimicrob Agents Chemother. 1996. PMID: 8834883 Free PMC article.

5

Immune response to Clostridium difficile infection.

Kelly CP. Kelly CP. Eur J Gastroenterol Hepatol. 1996 Nov;8(11):1048-53. doi: 10.1097/00042737-199611000-00004. Eur J Gastroenterol Hepatol. 1996. PMID: 8944364 Review.

6

A human antibody binds to alpha-galactose receptors and mimics the effects of Clostridium difficile toxin A in rat colon.

Pothoulakis C, Galili U, Castagliuolo I, Kelly CP, Nikulasson S, Dudeja PK, Brasitus TA, LaMont JT. Pothoulakis C, et al. Among authors: kelly cp. Gastroenterology. 1996 Jun;110(6):1704-12. doi: 10.1053/gast.1996.v110.pm8964394. Gastroenterology. 1996. PMID: 8964394

7

Intravenous immunoglobulin therapy for severe Clostridium difficile colitis.

Salcedo J, Keates S, Pothoulakis C, Warny M, Castagliuolo I, LaMont JT, Kelly CP. Salcedo J, et al. Among authors: kelly cp. Gut. 1997 Sep;41(3):366-70. doi: 10.1136/gut.41.3.366. Gut. 1997. PMID: 9378393 Free PMC article.

8

Clostridium difficile infection.

Kelly CP, LaMont JT. Kelly CP, et al. Annu Rev Med. 1998;49:375-90. doi: 10.1146/annurev.med.49.1.375. Annu Rev Med. 1998. PMID: 9509270 Review.

9

Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine.

Warny M, Fatimi A, Bostwick EF, Laine DC, Lebel F, LaMont JT, Pothoulakis C, Kelly CP. Warny M, et al. Among authors: kelly cp. Gut. 1999 Feb;44(2):212-7. doi: 10.1136/gut.44.2.212. Gut. 1999. PMID: 9895380 Free PMC article. Clinical Trial.

10

Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

Kyne L, Warny M, Qamar A, Kelly CP. Kyne L, et al. Among authors: kelly cp. N Engl J Med. 2000 Feb 10;342(6):390-7. doi: 10.1056/NEJM200002103420604. N Engl J Med. 2000. PMID: 10666429 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

343 results

Search Page

Filters